JPRN-jRCT2080222961未知3 期
Phase 3 Study of KHK7580 (A Randomized, Double-Blind, Intra-Subject Dose-Adjustment, Parallel-Group Study of KHK7580 and Cinacalcet Hydrochloride in Subjects with Secondary Hyperparathyroidism Receiving Hemodialysis)
Kyowa Hakko Kirin Co., Ltd.0 个研究点目标入组 600 人开始时间: 2015年9月10日最近更新:
试验速览
- 阶段
- 3 期
- 发起方
- 入组人数
- 600
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Personally submitted written voluntary informed consent to participate in the study
- •- Stable chronic renal disease treated with hemodialysis 3 times weekly for at least 12 weeks before screening
- •- Mean intact parathyroid hormone (PTH) level of > 240 pg/ml at screening, at 2 weeks and 1 week before the start of study treatment
排除标准
- 未提供
研究者
相似试验
未知
3 期
Phase 3 long-term study of KHK7580JPRN-jRCT2080222963Kyowa Hakko Kirin Co., Ltd.120
未知
3 期
Phase 3 study of KHK7580Secondary hyperparathyroidism receiving peritoneal dialysisJPRN-jRCT2080222964Kyowa Hakko Kirin Co., Ltd.30
已完成
2 期
Phase 3 Study of KHK7580Secondary HyperparathyroidismNCT02549391Kyowa Kirin Co., Ltd.634
未知
1 期
Phase 1 study of KHK7580JPRN-jRCT2080222486Kyowa Hakko Kirin Co., Ltd.8
已完成
3 期
Phase 3 Study of KHK7580Secondary HyperparathyroidismNCT02549417Kyowa Kirin Co., Ltd.39